Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 170 publications
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Journal: Science advances
Published: September 04, 2026
Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals.
Journal: medRxiv : the preprint server for health sciences
Published: May 04, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.
Journal: Cancer discovery
Published: December 31, 2025
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.
Journal: Nature communications
Published: December 02, 2025
Assessment of colorectal cancer recurrence risk following solid organ transplantation.
Journal: Journal of gastrointestinal oncology
Published: November 25, 2025
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025
Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.
Journal: Frontiers in immunology
Published: September 29, 2025
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2025
Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 01, 2025
Last Updated: 09/26/2026